
|Articles|October 1, 2001
Four immunoassays offer 14 in vitro tumor markers
Los Angeles-Diagnostic Products Corp., has been granted FDA approval to market four PSA immunoassays for prostate cancer detection: Immulite PSA, Immulite 2000 PSA, Immulite Third Generation PSA, and Immulite 2000 Third Generation PSA. The assays are intended for in vitro diagnostic use with the Immulite and Immulite 2000 immunoassay analyzers.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
3
Study suggests potential diuretic effect with nadofaragene firadenovec
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











